New oral agents for type II diabetes. Taking a more aggressive approach to therapy.
Status quo obviously is not optimal in the management of patients with non-insulin-dependent diabetes, given the fact that the average hemoglobin A1c value in this diabetic population is between 9% and 10%. There is an impetus, therefore, to move up the treatment ladder more quickly than at present. The availability of new oral hypoglycemic agents provides the potential for expanding the role of this category of agents and for improving overall glycemic control in these patients.
Hollander
P A
PA
Division of Endocrinology and Diabetes, International Diabetes Center, Park Nicollet Medical Center, Minneapolis, USA.
D000284:Administration, Oral; D001645:Biguanides / Q000008:administration & dosage; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004334:Drug Administration Schedule; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D013453:Sulfonylurea Compounds / Q000008:administration & dosage
D001645:Biguanides; D065089:Glycoside Hydrolase Inhibitors; D013453:Sulfonylurea Compounds